Skip to main content
BioAge Labs, Inc. logo

BioAge Labs, Inc. — Investor Relations & Filings

Ticker · BIOA ISIN · US09077V1008 LEI · 529900NG0C40250Z7875 US Manufacturing
Filings indexed 129 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country US United States of America
Listing US BIOA

About BioAge Labs, Inc.

https://bioagelabs.com

BioAge Labs, Inc. is a clinical-stage biotechnology company that develops therapies for metabolic diseases by targeting the molecular mechanisms of human aging. The company's mission is to extend healthy lifespan. It utilizes a proprietary, human-first discovery platform that analyzes multi-omics data from longitudinal biobanks to identify novel targets that drive aging and disease. BioAge's therapeutic pipeline focuses on cardiometabolic conditions such as obesity and cardiovascular disease. Key programs include BGE-102, an NLRP3 inhibitor designed to block chronic inflammation, and an apelin receptor (APJ) agonist that functions as an exercise mimetic to improve body composition and enhance weight loss.

Recent filings

Filing Released Lang Actions
8-K - BioAge Labs, Inc. (0001709941) (Filer)
Regulatory Filings
2026-05-08 English
10-Q - BioAge Labs, Inc. (0001709941) (Filer)
Interim / Quarterly Report
2026-05-08 English
S-3ASR - BioAge Labs, Inc. (0001709941) (Filer)
Registration Form
2026-03-24 English
S-8 - BioAge Labs, Inc. (0001709941) (Filer)
Registration Form
2026-03-24 English
10-K - BioAge Labs, Inc. (0001709941) (Filer)
Annual Report FY 2025
2026-03-24 English
8-K - BioAge Labs, Inc. (0001709941) (Filer)
Regulatory Filings
2026-03-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.